

# Benjamin Kearns

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1307551/publications.pdf>

Version: 2024-02-01

35  
papers

1,005  
citations

566801

15  
h-index

433756

31  
g-index

37  
all docs

37  
docs citations

37  
times ranked

1701  
citing authors

#	ARTICLE	IF	CITATIONS
1	Legacy and Emerging Perfluoroalkyl Substances Are Important Drinking Water Contaminants in the Cape Fear River Watershed of North Carolina. <i>Environmental Science and Technology Letters</i> , 2016, 3, 415-419.	3.9	444
2	Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample. <i>European Journal of Health Economics</i> , 2015, 16, 141-151.	1.4	62
3	Association between body mass index and health-related quality of life, and the impact of self-reported long-term conditions " cross-sectional study from the south Yorkshire cohort dataset. <i>BMC Public Health</i> , 2013, 13, 1009.	1.2	37
4	Patterns of multimorbidity and their association with health outcomes within Yorkshire, England: baseline results from the Yorkshire Health Study. <i>BMC Public Health</i> , 2016, 16, 649.	1.2	35
5	Predicting the prevalence of chronic kidney disease in the English population: a cross-sectional study. <i>BMC Nephrology</i> , 2013, 14, 49.	0.8	31
6	Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. <i>British Journal of Surgery</i> , 2013, 100, 1180-1188.	0.1	31
7	Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2013, 31, 479-488.	1.7	29
8	Cohort Profile: The Yorkshire Health Study. <i>International Journal of Epidemiology</i> , 2016, 45, 707-712.	0.9	29
9	A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. <i>Medical Decision Making</i> , 2019, 39, 899-909.	1.2	28
10	Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis. <i>Health Technology Assessment</i> , 2014, 18, 1-252.	1.3	26
11	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. <i>Pharmacoeconomics</i> , 2020, 38, 193-204.	1.7	25
12	Generalized Linear Models for Flexible Parametric Modeling of the Hazard Function. <i>Medical Decision Making</i> , 2019, 39, 867-878.	1.2	24
13	Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. <i>BMC Medicine</i> , 2016, 14, 200.	2.3	23
14	The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. <i>Health Technology Assessment</i> , 2017, 21, 1-536.	1.3	23
15	Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations. <i>Pharmacoeconomics</i> , 2013, 31, 643-652.	1.7	21
16	Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme. <i>British Journal of Cancer</i> , 2014, 111, 1734-1741.	2.9	16
17	The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. <i>BMC Health Services Research</i> , 2017, 17, 78.	0.9	16
18	Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 125-137.	1.0	12

#	ARTICLE	IF	CITATIONS
19	The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study. <i>Value in Health</i> , 2021, 24, 1634-1642.	0.1	12
20	Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study. <i>BMC Medical Research Methodology</i> , 2021, 21, 263.	1.4	12
21	Innovation in health economic modelling of service improvements for longer-term depression: demonstration in a local health community. <i>BMC Health Services Research</i> , 2013, 13, 150.	0.9	10
22	Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. <i>BMJ Open</i> , 2017, 7, e013460.	0.8	10
23	Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar Disorder in Children and Adolescents: A NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2013, 31, 981-990.	1.7	9
24	Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm. <i>British Journal of Cancer</i> , 2016, 114, 327-333.	2.9	7
25	Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 415-424.	1.7	7
26	The association between long-term conditions and uptake of population-based screening for colorectal cancer: results from two English cohort studies. <i>Cancer Management and Research</i> , 2018, Volume 10, 637-645.	0.9	6
27	External Validation of a Colorectal Cancer Model Against Screening Trial Long-Term Follow-Up Data. <i>Value in Health</i> , 2019, 22, 1154-1161.	0.1	4
28	Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. <i>Health Services and Outcomes Research Methodology</i> , 2022, 22, 317-331.	0.8	4
29	Optimizing the Design of a Repeated Fecal Immunochemical Test Bowel Cancer Screening Programme With a Limited Endoscopy Capacity From a Health Economic Perspective. <i>Value in Health</i> , 2022, 25, 954-964.	0.1	4
30	The Incidence and Costs of Adverse Events Associated with Antidepressants: Results from a Systematic Review, Network Meta-Analysis and Multi-Country Economic Model. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1133-1143.	1.0	4
31	Predicting preference-based utility values using partial proportional odds models. <i>BMC Research Notes</i> , 2014, 7, 438.	0.6	3
32	Dynamic and Flexible Survival Models for Extrapolation of Relative Survival: A Case Study and Simulation Study. <i>Medical Decision Making</i> , 2022, 42, 945-955.	1.2	1
33	Should There Be an Option to “Unrefer” NICE Single Technology Appraisals: Case Study of Aripiprazole for Bipolar I Disorder in Adolescents. <i>Value in Health</i> , 2013, 16, A615-A616.	0.1	0
34	Improved identification of people at risk of psychosis: is it value for money?. <i>Lancet Psychiatry</i> , the, 2015, 2, 951-952.	3.7	0
35	PMU13 Schizophrenia Treatment with Second-Generation Antipsychotics: A MULTI-Country Evaluation of the Costs of Cardiovascular and Metabolic Adverse Events and Weight GAIN. <i>Value in Health</i> , 2020, 23, S605.	0.1	0